Potential of Alzheimer's Medication to Improve Social Skills in Youth with Autism
A groundbreaking study suggests that memantine, an Alzheimer's drug, may enhance social skills in youth with autism, especially those with elevated brain glutamate levels, paving the way for personalized treatments.
Recent research led by Mass General Brigham indicates that a medication originally developed for Alzheimer's disease, memantine, may have promising effects on social impairments in some children and adolescents with autism spectrum disorder (ASD). Autism affects over 2% of children and is characterized by difficulties in social interaction and communication. While prior studies exploring glutamate-modulating treatments like memantine have yielded mixed results, this new study sheds light on specific biomarkers that could predict treatment response.
Some individuals with ASD exhibit abnormal levels of glutamate, a key neurotransmitter involved in brain signaling. In a 12-week randomized controlled trial involving 42 participants aged 8 to 18 years without intellectual disabilities, researchers found that memantine significantly improved social behaviors more than a placebo. Notably, participants with elevated glutamate levels in the pregenual anterior cingulate cortex (pgACC)—a brain region vital for social processing—responded particularly well to the treatment. Among these, 80% showed improvement, suggesting that measuring glutamate levels could help identify who might benefit most.
The trial also included brain scans of participants, revealing that those with higher glutamate levels saw greater benefits from memantine, which was generally well tolerated with mild side effects like headaches. These findings imply that pgACC glutamate measurement could serve as a biomarker for targeting treatment to individuals most likely to respond.
Dr. Gagan Joshi emphasized that while the drug helped improve social engagement and reduce autism severity, it did not eliminate all symptoms, indicating the need for further research. Larger clinical trials are planned to validate these findings and explore whether high glutamate levels can predict responses to other glutamate-modulating therapies.
The study’s results are published in JAMA Network Open source. This innovative approach highlights the potential for personalized treatment strategies, offering hope for improving social functioning in youth with ASD.
Source: https://medicalxpress.com/news/2025-10-alzheimer-disease-medication-social-impairment.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Experts Confirm No Link Between Paracetamol Use During Pregnancy and Autism Risk
Scientific research confirms that paracetamol use during pregnancy does not increase autism risks. Experts warn against misinformation that can cause unnecessary anxiety among expectant mothers.
Immune System Aging as a Potential Cause of Rheumatoid Arthritis
New research suggests that immune system aging may be a key factor in the development of rheumatoid arthritis, opening avenues for early prediction and preventative treatments.
Underutilization of Effective Treatments in High-Risk Myelodysplastic Syndromes Revealed by New Study
A recent study reveals that many high-risk myelodysplastic syndrome patients do not receive or complete guideline-recommended hypomethylating agent therapy, highlighting a significant gap in care and disparities among populations.
Early Indicators of Valve Failure Detected One Year Post-Transcatheter Aortic Valve Implantation
A study has identified early signs of heart valve deterioration within one year following transcatheter aortic valve implantation (TAVI), raising concerns about device longevity in younger patients.